撕成碎片
发表于 2025-3-21 17:35:21
书目名称Congenital Bleeding Disorders影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0235475<br><br> <br><br>书目名称Congenital Bleeding Disorders影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0235475<br><br> <br><br>书目名称Congenital Bleeding Disorders网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0235475<br><br> <br><br>书目名称Congenital Bleeding Disorders网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0235475<br><br> <br><br>书目名称Congenital Bleeding Disorders被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0235475<br><br> <br><br>书目名称Congenital Bleeding Disorders被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0235475<br><br> <br><br>书目名称Congenital Bleeding Disorders年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0235475<br><br> <br><br>书目名称Congenital Bleeding Disorders年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0235475<br><br> <br><br>书目名称Congenital Bleeding Disorders读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0235475<br><br> <br><br>书目名称Congenital Bleeding Disorders读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0235475<br><br> <br><br>
Mnemonics
发表于 2025-3-21 21:57:58
Merete Christiansen,Carsten K. Hansenessment. On-demand therapy is the mainstay of treatment in VWD, although long-term prophylaxis is emerging for those with recurrent and severe bleeding. Therapeutic choices in VWD depend to some extent on geographical location, but include VWF/FVIII concentrates, recombinant VWF, and desmopressin.
我还要背着他
发表于 2025-3-22 03:36:51
http://reply.papertrans.cn/24/2355/235475/235475_3.png
nonsensical
发表于 2025-3-22 08:08:26
Christer Jönsson,Jonas Tallbergsma (FFP), plasma-derived FVII (pd-FVII), prothrombin complex concentrate (PCC), activated PCC (aPCC), and more recently, recombinant activated FVII (rFVIIa) are available for treatment of patients with FVII deficiency. New therapeutic options significantly improved the quality of life in patients with congenital FVII deficiency.
mitten
发表于 2025-3-22 11:19:41
https://doi.org/10.1007/978-3-030-60679-4aterial positive (CRM+). Different therapeutic choices are available, including fresh frozen plasma and FXI concentrate. However, plasma and factor XI concentrates can provoke inhibitor formation. Recombinant FVIIa treatment can be used for such patients.
Charlatan
发表于 2025-3-22 15:23:14
von Willebrand Disease: An Update on Diagnosis and Treatmentessment. On-demand therapy is the mainstay of treatment in VWD, although long-term prophylaxis is emerging for those with recurrent and severe bleeding. Therapeutic choices in VWD depend to some extent on geographical location, but include VWF/FVIII concentrates, recombinant VWF, and desmopressin.
Charlatan
发表于 2025-3-22 20:41:56
http://reply.papertrans.cn/24/2355/235475/235475_7.png
悠然
发表于 2025-3-22 21:30:01
Congenital Factor VII Deficiency, Diagnosis, and Managementsma (FFP), plasma-derived FVII (pd-FVII), prothrombin complex concentrate (PCC), activated PCC (aPCC), and more recently, recombinant activated FVII (rFVIIa) are available for treatment of patients with FVII deficiency. New therapeutic options significantly improved the quality of life in patients with congenital FVII deficiency.
详细目录
发表于 2025-3-23 01:59:21
http://reply.papertrans.cn/24/2355/235475/235475_9.png
OREX
发表于 2025-3-23 08:21:27
http://reply.papertrans.cn/24/2355/235475/235475_10.png